PAMS
TCRT icon

Pictet Asset Management (Switzerland)’s Alaunos Therapeutics TCRT Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-142
Closed -$14K – 1684
2022
Q1 		$14K Hold
142
– – ﹤0.01% 1680
2021
Q4 		$23K Hold
142
– – ﹤0.01% 1716
2021
Q3 		$39K Buy
+142
New +$43.4K ﹤0.01% 1735

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s TCRT Position: Q2 2022 in Review

Pictet Asset Management (Switzerland) sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 142 shares — an estimated $14K sold.

Pictet Asset Management (Switzerland) first reported a position in TCRT in Q3 2021 and held it in 3 quarters. The position peaked at $39K in Q3 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Pictet Asset Management (Switzerland) reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Pictet Asset Management (Switzerland) sold 142 Alaunos Therapeutics shares in Q2 2022, an estimated $14K.
  • Pictet Asset Management (Switzerland) first reported a position in Alaunos Therapeutics in Q3 2021 and held it in 3 quarters.
  • Pictet Asset Management (Switzerland)'s Alaunos Therapeutics position peaked at $39K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2022, filed 9 Aug 2022.